To UM home page

Researcher

Yaromina, A.

Researcher

View graph of relations
1 - 35 out of 35Page size: 50
  1. 2019
  2. Published
    Spiegelberg, L., Houben, R., Niemans, R., de Ruysscher, D., Yaromina, A., Theys, J., ... Dubois, L. J. (2019). Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. Clinical and Translational Radiation Oncology, 15, 62-69. https://doi.org/10.1016/j.ctro.2019.01.005
  3. Published
    Roig, E. M., Groot, A. J., Yaromina, A., Hendrickx, T. C., Barbeau, L. M. O., Giuranno, L., ... Vooijs, M. A. (2019). HIF-1 alpha and HIF-2 alpha Differently Regulate the Radiation Sensitivity of NSCLC Cells. Cells, 8(1), [45]. https://doi.org/10.3390/cells8010045
  4. Published
    Iglesias, V. S., van Hoof, S. J., Vaniqui, A., Schyns, L. E., Lieuwes, N., Yaromina, A., ... Vooijs, M. (2019). An orthotopic non-small cell lung cancer model for image-guided small animal radiotherapy platforms. British Journal of Radiology, 92(1095), [20180476]. https://doi.org/10.1259/bjr.20180476
  5. Published
    Meaney, C., Powathil, G. G., Yaromina, A., Dubois, L. J., Lambin, P., & Kohandel, M. (2019). Role of hypoxia-activated prodrugs in combination with radiation therapy: An in silico approach. Mathematical Biosciences and Engineering, 16(6), 6257-6273. https://doi.org/10.3934/mbe.2019312
  6. 2018
  7. Published
    Iglesias, V. S., Theys, J., Groot, A. J., Barbeau, L. M. O., Lemmens, A., Yaromina, A., ... Vooijs, M. (2018). Synergistic Effects of NOTCH/gamma-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells. Frontiers in Oncology, 8, [460]. https://doi.org/10.3389/fonc.2018.00460
  8. Published
    Roig, E. M., Yaromina, A., Houben, R., Groot, A. J., Dubois, L., & Vooijs, M. (2018). Prognostic Role of Hypoxia-Inducible Factor-2α Tumor Cell Expression in Cancer Patients: A Meta-Analysis. Frontiers in Oncology, 8, [224]. https://doi.org/10.3389/fonc.2018.00224
  9. Published
    Rekers, N. H., Pimentel, V. O., Yaromina, A., Lieuwes, N. G., Biemans, R., Zegers, C. M. L., ... Lambin, P. (2018). The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. OncoImmunology , 7(4), [e1414119]. https://doi.org/10.1080/2162402X.2017.1414119
  10. Published
    Kazokaite, J., Niemans, R., Dudutiene, V., Becker, H. M., Leitans, J., Zubriene, A., ... Matulis, D. (2018). Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells. Oncotarget, 9(42), 26800-26816. https://doi.org/10.18632/oncotarget.25508
  11. 2017
  12. Published
    Peerlings, J., Van De Voorde, L., Mitea, C., Larue, R., Yaromina, A., Sandeleanu, S., ... Mottaghy, F. M. (2017). Hypoxia and hypoxia response-associated molecular markers in esophageal cancer: A systematic review. Methods, 130, 51-62. https://doi.org/10.1016/j.ymeth.2017.07.002
  13. Published
    Troost, E. G. C., Koi, L., Yaromina, A., & Krause, M. (2017). Therapeutic options to overcome tumor hypoxia in radiation oncology. Clinical and Translational Imaging, 5(5), 455-464. https://doi.org/10.1007/s40336-017-0247-6
  14. Published
    Yaromina, A., Granzier, M., Biemans, R., Lieuwes, N., van Elmpt, W., Shakirin, G., ... Lambin, P. (2017). A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the "Low Drug Uptake Volume". Radiotherapy and Oncology, 124(3), 513-520. https://doi.org/10.1016/j.radonc.2017.04.020
  15. Published
    De-Colle, C., Yaromina, A., Hennenlotter, J., Thames, H., Mueller, A-C., Neumann, T., ... Menegakis, A. (2017). Ex vivo gamma H2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity. Radiotherapy and Oncology, 124(3), 386-394. https://doi.org/10.1016/j.radonc.2017.08.020
  16. Published
    van Kuijk, S. J. A., Parvathaneni, N. K., Niemans, R., van Gisbergen, M. W., Carta, F., Vullo, D., ... Lambin, P. (2017). New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs. European Journal of Medicinal Chemistry, 127, 691-702. https://doi.org/10.1016/j.ejmech.2016.10.037
  17. Published
    Lambin, P., Zindler, J., Vanneste, B. G. L., Van De Voorde, L., Eekers, D., Compter, I., ... Walsh, S. (2017). Decision support systems for personalized and participative radiation oncology. Advanced Drug Delivery Reviews, 109, 131-153. https://doi.org/10.1016/j.addr.2016.01.006
  18. Published
    Van Limbergen, E. J., De Ruysscher, D. K., Pimentel, V. O., Marcus, D., Berbee, M., Hoeben, A., ... Lambin, P. (2017). Combining radiotherapy with immunotherapy: the past, the present and the future. British Journal of Radiology, 90(1076), [20170157]. https://doi.org/10.1259/bjr.20170157
  19. 2016
  20. Published
    Jentsch, C., Bergmann, R., Bruechner, K., Mosch, B., Yaromina, A., Krause, M., ... Beuthien-Baumann, B. (2016). Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours. Radiotherapy and Oncology, 121(3), 447-452. https://doi.org/10.1016/j.radonc.2016.07.024
  21. Published
    Rekers, N. H., Pimentel, V. O., Yaromina, A., Dubois, L., & Lambin, P. (2016). IL2 based immunotherapies: towards a personalized and curative antitumor response. Translational Cancer Research, 5(Suppl 6), S1292-S1294. https://doi.org/10.21037/tcr.2016.11.26
  22. Published
    van Kuijk, S. J. A., Gieling, R. G., Niemans, R., Lieuwes, N. G., Biemans, R., Telfer, B. A., ... Williams, K. J. (2016). The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy. PLOS ONE, 11(8), [e0161040]. https://doi.org/10.1371/journal.pone.0161040
  23. Published
    Sneddon, D., Niemans, R., Bauwens, M., Yaromina, A., van Kuijk, S. J. A., Lieuwes, N. G., ... Poulsen, S-A. (2016). Synthesis and in Vivo Biological Evaluation of Ga-68-Labeled Carbonic Anhydrase IX Targeting Small Molecules for Positron Emission Tomography. Journal of Medicinal Chemistry, 59(13), 6431-6443. https://doi.org/10.1021/acs.jmedchem.6b00623
  24. Published
    Wack, L. J., Moennich, D., Yaromina, A., Zips, D., Baumann, M., & Thorwarth, D. (2016). Correlation of FMISO simulations with pimonidazole-stained tumor xenografts: A question of O-2 consumption? Medical Physics, 43(7), 4113-4121. https://doi.org/10.1118/1.4951728
  25. Published
    van Kuijk, S. J. A., Yaromina, A., Houben, R., Niemans, R., Lambin, P., & Dubois, L. J. (2016). Prognostic Significance of Carbonic Anhydrase IX expression in Cancer Patients: A Meta-Analysis. Frontiers in Oncology, 6, [69]. https://doi.org/10.3389/fonc.2016.00069
  26. Published
    Panth, K. M., van den Beucken, T., Biemans, R., Lieuwes, N. G., Weber, M., Losen, M., ... Lambin, P. (2016). In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity. Scientific Reports, 6, [22198]. https://doi.org/10.1038/srep22198
  27. 2015
  28. Published
    Trani, D., Yaromina, A., Dubois, L., Granzier, M., Peeters, S. G. J. A., Biemans, R., ... Lambin, P. (2015). Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake. Clinical Cancer Research, 21(24), 5511-5518. https://doi.org/10.1158/1078-0432.CCR-15-0290
  29. Published
    Rekers, N. H., Zegers, C. M. L., Yaromina, A., Lieuwes, N. G., Biemans, R., Senden-Gijsbers, B. L. M. G., ... Lambin, P. (2015). Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model. Radiotherapy and Oncology, 116(3), 438-442. https://doi.org/10.1016/j.radonc.2015.06.019
  30. Published
    Menegakis, A., von Neubeck, C., Yaromina, A., Thames, H., Hering, S., Hennenlotter, J., ... Baumann, M. (2015). gamma H2AX assay in ex vivo irradiated tumour specimens: A novel Method to determine tumour radiation sensitivity in patient-derived material. Radiotherapy and Oncology, 116(3), 473-479. https://doi.org/10.1016/j.radonc.2015.03.026
  31. Published
    Panth, K. M., Leijenaar, R. T. H., Carvalho, S., Lieuwes, N. G., Yaromina, A., Dubois, L., & Lambin, P. (2015). Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible GADD34 tumor cells. Radiotherapy and Oncology, 116(3), 462-466. https://doi.org/10.1016/j.radonc.2015.06.013
  32. Published
    Dubois, L. J., Niemans, R., van Kuijk, S. J. A., Panth, K. M., Parvathaneni, N-K., Peeters, S. G. J. A., ... Lambin, P. (2015). New ways to image and target tumour hypoxia and its molecular responses. Radiotherapy and Oncology, 116(3), 352-357. https://doi.org/10.1016/j.radonc.2015.08.022
  33. Published
    Peeters, S. G. J. A., Zegers, C. M. L., Biemans, R., Lieuwes, N. G., van Stiphout, R. G. P. M., Yaromina, A., ... Lambin, P. (2015). TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [F-18]HX4 Hypoxia PET Imaging. Clinical Cancer Research, 21(13), 2984-2992. https://doi.org/10.1158/1078-0432.CCR-15-0018
  34. Published
    Trani, D., Reniers, B., Persoon, L., Podesta, M., Nalbantov, G., Leijenaar, R. T. H., ... Lambin, P. (2015). What Level of Accuracy Is Achievable for Preclinical Dose Painting Studies on a Clinical Irradiation Platform? Radiation Research, 183(5), 501-510. https://doi.org/10.1667/RR13933.1
  35. Published
    Peeters, S. G. J. A., Zegers, C. M. L., Yaromina, A., Van Elmpt, W., Dubois, L., & Lambin, P. (2015). Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 59(1), 39-57.
  36. Published
    Zegers, C. M. L., Rekers, N. H., Quaden, D. H. F., Lieuwes, N. G., Yaromina, A., Germeraad, W. T. V., ... Lambin, P. (2015). Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects. Clinical Cancer Research, 21(5), 1151-1160. https://doi.org/10.1158/1078-0432.CCR-14-2676
  37. 2014
  38. Published
    Helbig, L., Koi, L., Bruechner, K., Gurtner, K., Hess-Stumpp, H., Unterschemmann, K., ... Yaromina, A. (2014). BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts. Radiation Oncology, 9, [207]. https://doi.org/10.1186/1748-717X-9-207
  39. Published
    Schuetze, C., Bergmann, R., Bruechner, K., Mosch, B., Yaromina, A., Zips, D., ... Beuthien-Baumann, B. (2014). Effect of [F-18]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. Radiotherapy and Oncology, 111(1), 81-87. https://doi.org/10.1016/j.radonc.2014.02.005
  40. Published
    Helbig, L., Koi, L., Bruechner, K., Gurtner, K., Hess-Stumpp, H., Unterschemmann, K., ... Zips, D. (2014). Hypoxia-Inducible Factor Pathway Inhibition Resolves Tumor Hypoxia and Improves Local Tumor Control After Single-Dose Irradiation. International Journal of Radiation Oncology Biology Physics, 88(1), 159-166. https://doi.org/10.1016/j.ijrobp.2013.09.047
  41. 2013
  42. Published
    Dubois, L., Peeters, S. G. J. A., van Kuijk, S. J. A., Yaromina, A., Lieuwes, N. G., Saraya, R., ... Lambin, P. (2013). Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs. Radiotherapy and Oncology, 108(3), 523-528. https://doi.org/10.1016/j.radonc.2013.06.018

UM personal profile

UM postal address
P.O. Box 616
6200 MD Maastricht
The Netherlands

UM visiting address
Minderbroedersberg 4-6
6211 LK Maastricht
The Netherlands
Phone: +31 43 388 2222

Quick Links